Oculus Innovative Sciences, Inc. Logo

Print Print page | Email Email page | PDF Download PDF | Add to Briefcase Add to briefcase
« Previous Release | Next Release »



Oculus Schedules Fiscal Fourth Quarter and Full Year 2007 Financial Results Release and Conference Call

PETALUMA, Calif., Jun 06, 2007 (BUSINESS WIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that financial results for the fiscal fourth quarter and year ended March 31, 2007, will be released before the U.S. market opens on June 7, 2007.

The earnings release will be followed by a conference call at 1:05 p.m. PDT (4:05 p.m. EDT) on June 7, 2007, to discuss fiscal 2007 results and recent clinical and business development activities.

A live audiocast over the Internet will be available at http://ir.oculusis.com/events.cfm and will be archived for 30 days.

To listen over the phone, please call 1-877-407-4018 (domestic/toll-free) or 1-201-689-8471 (international). A telephone replay will be available for 48 hours after the call at 1-877-660-6853 (domestic/toll-free), or 1-201-612-7415 (international). Please enter account number 3055 and conference identification number 244652.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.

SOURCE: Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Dan McFadden, 425-753-2105
dmcfadden@oculusis.com
or
The Ruth Group (investors)
Sara Ephraim, 646-536-7002
sephraim@theruthgroup.com
or
The Ruth Group (media)
Jason Rando, 646-536-7025
jrando@theruthgroup.com
Janine McCargo, 646-536-7033
jmccargo@theruthgroup.com

Copyright Business Wire 2007

News Provided by COMTEX

Close window | Back to top